Congress expands fentanyl sanctions to target China, Mexico, India
S. 860 — BUST FENTANYL Act · Filed by James Risch (R-ID) · 3 cosponsors · Introduced Mar 5, 2025 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill strengthens U.S. efforts to combat fentanyl and methamphetamine trafficking by requiring the State Department and Attorney General to report on efforts to pressure China, India, Mexico, and other countries to control precursor chemicals and stop illicit drug production; expanding presidential authority to sanction foreign individuals, entities, and government agencies involved in opioid trafficking; and requiring annual reports on methamphetamine smuggling from Mexico. The bill prioritizes identification of Chinese persons and entities in the fentanyl supply chain for sanctions purposes.
Why we flagged it
The bill's core mechanism is expansion of presidential sanctions authority and diplomatic/law-enforcement reporting requirements targeting foreign actors and governments involved in fentanyl and methamphetamine trafficking. It is a public-safety and foreign-policy instrument, not a domestic regulatory or commercial measure.
What the text implies
- Prioritization of Chinese entities for sanctions may accelerate financial decoupling between U.S. and Chinese financial systems if sanctions are broadly applied to PRC-linked money laundering organizations.
- The bill's requirement that the President certify when China is 'no longer the primary source' for fentanyl precursors creates an indefinite sanctions regime unless that threshold is met, potentially locking in sanctions policy beyond 2030.
- Expansion of sanctions to foreign government agencies and their senior officials may create diplomatic friction with countries like Mexico and India, which are named as significant sources but are also U.S. allies.
- The bill does not specify enforcement mechanisms or appropriations for DEA office establishment in China, leaving implementation dependent on future diplomatic success and budget allocation.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill expands law-enforcement and diplomatic tools to disrupt international drug trafficking networks that directly harm American citizens through overdose deaths and addiction. It imposes no new restrictions on citizens' rights or remedies, and the sanctions authority targets foreign actors and governments complicit in narcotics trafficking, not domestic populations.
Who stands to gain
- law enforcement agencies (DEA, FBI, ICE)
- defense and security contractors supporting international operations
- pharmaceutical companies subject to precursor chemical controls (potential compliance cost offset by
Named in the bill
Drug Enforcement Administration (DEA), State Department, Attorney General, People's Republic of China (PRC), Mexico, India, Canada, Trilateral Fentanyl Committee, Global Coalition to Address Synthetic Drug Threats, Fentanyl Sanctions Act, Combat Methamphetamine Epidemic Act of 2005
Where it stands
3 cosponsors: 2 Democrats, 1 Republicans.
- Mar 5, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Mar 5, 2025 — Referred to Senate Committee on Foreign Relations · Congress.gov: “Read twice and referred to the Committee on Foreign Relations”
- Mar 27, 2025 — Reported out of committee · Congress.gov: “Committee on Foreign Relations. Ordered to be reported without amendment favorably”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $150,000 in lobbying spend. A filing names 17 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
James Risch, the sponsor, reported $1,209,927 in PAC receipts in the 2026 cycle.
- Rsm Us Llp (formerly Known As Mcgladrey Llp) — $150,000 on 1 filing
Lobbying Disclosure Act filings through Jul 19, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (9,897 characters) on Aug 21, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 19, 2026 · page rendered 2026-10-20.
“Congress expands fentanyl sanctions to target China, Mexico, India” QuorumCivic. https://share.quorumcivic.app/bill/119/s860 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.